Syntara Ltd

AU:SNT Australia Drug Manufacturers - Specialty & Generic
Market Cap
$31.35 Million
AU$50.62 Million AUD
Market Cap Rank
#24655 Global
#511 in Australia
Share Price
AU$0.03
Change (1 day)
+3.33%
52-Week Range
AU$0.02 - AU$0.08
All Time High
AU$0.40
About

Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and i… Read more

Syntara Ltd (SNT) - Total Assets

Latest total assets as of June 2025: AU$21.44 Million AUD

Based on the latest financial reports, Syntara Ltd (SNT) holds total assets worth AU$21.44 Million AUD as of June 2025.

Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Syntara Ltd - Total Assets Trend (2003–2025)

This chart illustrates how Syntara Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.

Syntara Ltd - Asset Composition Analysis

Current Asset Composition (June 2025)

Syntara Ltd's total assets of AU$21.44 Million consist of 97.8% current assets and 2.2% non-current assets.

Asset Category Amount (AUD) % of Total Assets
Cash & Equivalents AU$0.00 70.3%
Accounts Receivable AU$5.66 Million 26.4%
Inventory AU$0.00 0.0%
Property, Plant & Equipment AU$180.00K 0.8%
Intangible Assets AU$149.00K 0.7%
Goodwill AU$0.00 0.0%

Asset Composition Trend (2003–2025)

This chart illustrates how Syntara Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Syntara Ltd's current assets represent 97.8% of total assets in 2025, an increase from 90.1% in 2003.
  • Cash Position: Cash and equivalents constituted 70.3% of total assets in 2025, down from 89.6% in 2003.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 4.0% in 2003.
  • Asset Diversification: The largest asset category is accounts receivable at 26.4% of total assets.

Syntara Ltd Competitors by Total Assets

Key competitors of Syntara Ltd based on total assets are shown below.

Company Country Total Assets
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
USA $67.26 Billion
Kamada
NASDAQ:KMDA
USA $378.79 Million
One World Pharma Inc
OTCQB:OWPC
USA $6.62 Million
Dongwha Pharm.Co.Ltd
KO:000020
Korea ₩654.63 Billion
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
China CN¥27.28 Billion
Yuhan Corp.
KO:000100
Korea ₩3.05 Trillion
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
China CN¥4.97 Billion
Kotra Industries Bhd
KLSE:0002
Malaysia RM363.90 Million

Syntara Ltd - Asset Efficiency Metrics

Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.

Asset Turnover Ratio

Measures how efficiently a company uses its assets to generate sales

Historical Range: 0.11 - 0.52

Lower asset utilization - Syntara Ltd generates 0.35x its asset value in annual revenue.

Return on Assets (ROA)

Measures how efficiently a company uses its assets to generate profits

Historical Range: -145.86% - 12.83%

Negative ROA - Syntara Ltd is currently not profitable relative to its asset base.

Syntara Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 3.93 1.79 3.59
Quick Ratio 3.93 1.79 3.20
Cash Ratio 0.00 0.00 0.00
Working Capital AU$15.63 Million AU$ 4.32 Million AU$ 17.67 Million

Syntara Ltd - Advanced Valuation Insights

This section examines the relationship between Syntara Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 3.26
Latest Market Cap to Assets Ratio 1.12
Asset Growth Rate (YoY) 106.6%
Total Assets AU$21.44 Million
Market Capitalization $23.95 Million USD

Valuation Analysis

Above Book Valuation: The market values Syntara Ltd's assets above their book value (1.12 x), reflecting positive investor sentiment about the company's future prospects.

Rapid Asset Growth: Syntara Ltd's assets grew by 106.6% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Syntara Ltd (2003–2025)

The table below shows the annual total assets of Syntara Ltd from 2003 to 2025.

Year Total Assets Change
2025-06-30 AU$21.44 Million +106.56%
2024-06-30 AU$10.38 Million -56.79%
2023-06-30 AU$24.03 Million -4.61%
2022-06-30 AU$25.19 Million -25.02%
2021-06-30 AU$33.59 Million -5.16%
2020-06-30 AU$35.42 Million -32.76%
2019-06-30 AU$52.67 Million +5.13%
2018-06-30 AU$50.10 Million +10.26%
2017-06-30 AU$45.43 Million -30.80%
2016-06-30 AU$65.65 Million -20.48%
2015-06-30 AU$82.56 Million +23.69%
2014-06-30 AU$66.75 Million -40.55%
2013-06-30 AU$112.28 Million -14.75%
2012-06-30 AU$131.70 Million +39.26%
2011-06-30 AU$94.57 Million -32.82%
2010-06-30 AU$140.77 Million -14.16%
2009-06-30 AU$164.00 Million +31.15%
2008-06-30 AU$125.05 Million +51.30%
2007-06-30 AU$82.65 Million -20.73%
2006-06-30 AU$104.27 Million +174.84%
2005-06-30 AU$37.94 Million +34.24%
2004-06-30 AU$28.26 Million -5.15%
2003-06-30 AU$29.79 Million --